Stockholm, May 19, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, today announces an updated interim analysis of its AIR phase 2a trial with C21 in idiopathic pulmonary fibrosis (IPF). With 51 patients enrolled, the data demonstrates that C21 […]
BioInnovation Institute (BII) announces that it has entered a collaboration with Imperial College London (ICL) to launch a new translational project under its Bio Studio program. The program aims to foster the creation of new life science start-ups based on research from world-class scientists to benefit people and society. Read more…
The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy field Second SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro […]
Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a three-year research collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, USA. The objective of the collaboration is to determine the potential of NeoPhore’s proprietary DNA mismatch repair inhibitor (MMRi) compounds to enhance […]
Destiny Pharma announces start of a new XF-73 research programme Aim to test XF-73 as a potential preventive medicine for Oral Mucositis Oral Mucositis is a common and devastating complication from chemotherapy and radiotherapy suffered by more than 2m cancer patients every year Brighton, United Kingdom – 05 July 2022 – Destiny Pharma plc (AIM: DEST), […]